2017
PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study
Cremin I, McKinnon L, Kimani J, Cherutich P, Gakii G, Muriuki F, Kripke K, Hecht R, Kiragu M, Smith J, Hinsley W, Gelmon L, Hallett TB. PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study. The Lancet HIV 2017, 4: e214-e222. PMID: 28233660, DOI: 10.1016/s2352-3018(17)30021-8.Peer-Reviewed Original ResearchConceptsFemale sex workersMale sex workersKey populationsAntiretroviral therapySex workersHigh-risk female sex workersEarly antiretroviral therapyPre-exposure prophylaxisCombination HIV preventionRisk of infectionSpecific key populationsWider populationPrEP interventionsTherapy retentionHIV incidenceCombination preventionHIV transmissionCondom promotionHIV epidemicHIV preventionIncidence estimatesMathematical modelling studyMale circumcisionPrEPAverage annual spending
2011
Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries
Resch S, Korenromp E, Stover J, Blakley M, Krubiner C, Thorien K, Hecht R, Atun R. Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries. PLOS ONE 2011, 6: e25310. PMID: 21998648, PMCID: PMC3187775, DOI: 10.1371/journal.pone.0025310.Peer-Reviewed Original ResearchConceptsMiddle-income countriesAIDS treatmentProgram costsIncome countriesLarge health gainsAntiretroviral therapyHIV infectionOpportunistic infectionsGlobal FundLife careMedical treatmentAIDS diseaseTreatment programHealth gainsCurrent cohortTotal program costsTreatmentPatientsCohortInfectionCareEnd 2011Same periodEconomic benefitsLabor productivity effects
2010
Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009–31
Hecht R, Stover J, Bollinger L, Muhib F, Case K, de Ferranti D. Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009–31. The Lancet 2010, 376: 1254-1260. PMID: 20934597, DOI: 10.1016/s0140-6736(10)61255-x.Peer-Reviewed Original ResearchConceptsMiddle-income countriesLong-term funding needsLow-income countriesHIV/AIDS fundingOutside fundsPolicy choicesFunding needsStrategic investmentsEfficiency gainsEfficient mobilisationRepresentative countriesAIDS fundingCountriesFundsRange of scenariosShort termGlobal HIV/AIDS pandemicHIV/AIDS programsCostHIV/AIDS responseManagement of resourcesSubstantial variationFinancingInvestmentHIV/AIDS
2009
Critical Choices In Financing The Response To The Global HIV/AIDS Pandemic
Hecht R, Bollinger L, Stover J, McGreevey W, Muhib F, Madavo CE, de Ferranti D. Critical Choices In Financing The Response To The Global HIV/AIDS Pandemic. Health Affairs 2009, 28: 1591-1605. PMID: 19887401, DOI: 10.1377/hlthaff.28.6.1591.Peer-Reviewed Original Research
2007
The Impact Of An AIDS Vaccine In Developing Countries: A New Model And Initial Results
Stover J, Bollinger L, Hecht R, Williams C, Roca E. The Impact Of An AIDS Vaccine In Developing Countries: A New Model And Initial Results. Health Affairs 2007, 26: 1147-1158. PMID: 17630459, DOI: 10.1377/hlthaff.26.4.1147.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS VaccinesDeveloping CountriesDisease SusceptibilityDrug EvaluationFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedModels, StatisticalPatient SelectionProbabilityResearch Support as TopicRisk AssessmentRisk FactorsRisk-TakingSexual BehaviorSubstance Abuse, Intravenous